Over the course of nearly five decades, Biogen has played a major role in catalyzing and shaping Kendall Square in Cambridge, ...

Biogen's new management is diversifying its product portfolio and optimizing costs, but faces significant risks from market share loss and generic competition. The fair valuation of Biogen shares ...

The biotech company plans to move into the new development in 2028, consolidating other leased and owned spaces in the ...

With its move to MIT’s Volpe Center in Kendall Square, the drugmaker is consolidating its local footprint from three buildings to one In the first major deal at MIT’s ambitious overhaul of the ...

Biogen has announced a major revamp of its business that will see chief executive Michel Vounatsos depart the company, and all commercial activities related to troubled Alzheimer's therapy Aduhelm ...

Detailed price information for Biomarin Pharmaceuticals (BMRN-Q) from The Globe and Mail including charting and trades.